Copyright
©The Author(s) 2024.
World J Diabetes. Jun 15, 2024; 15(6): 1091-1110
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1091
Published online Jun 15, 2024. doi: 10.4239/wjd.v15.i6.1091
Figure 2 Summary of natural and synthetic compounds for treatment of obesity-related kidney disease.
H2S: Hydrogen sulfide; NF-κB: The nuclear factor-kappa B; AMPK: Adenosine 5-monophosphate activated protein kinase; ABCA1: ATP-binding cassette transporter; LPL: Lipoprotein lipase; OSBPL7: Oxysterol binding protein like 7; GRP55: G protein-coupled receptor 55; EPA: Eicosapentaenoic acid; IKK: IκB kinase.
- Citation: Mao TH, Huang HQ, Zhang CH. Clinical characteristics and treatment compounds of obesity-related kidney injury. World J Diabetes 2024; 15(6): 1091-1110
- URL: https://www.wjgnet.com/1948-9358/full/v15/i6/1091.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i6.1091